This site complies with the HONcode standard for trustworthy health information:
verify here.

Rewarding for
you and us
Defeat Diabetes Foundation

Defeat Diabetes
Foundation
150 153rd Ave,
Suite 300
Madeira Beach, FL 33708

FDA Orders New Safety Labels for Rosiglitazone (Avandia) and Pioglitazone (Actos)

Posted: Thursday, June 14, 2007

The FDA Commissioner Andrew C. von Eschenbach, M.D., told a congressional hearing that the FDA will beef up the cardiovascular warnings on the labels of both rosiglitazone (Avandia) and pioglitazone (Actos).

Moreover, the FDA announced it will convene a safety panel on June 30 to review the cardiovascular risks of rosiglitazone.

Rep. Henry Waxman (D-Calif.) convened the hearing to investigate the FDA's handling of rosiglitazone from its approval in 1999 through recent reports that linked the drug to increased risk of cardiovascular events.

In general, Dr. von Eschenbach defended the FDA's handling of rosiglitazone, but he conceded that the agency asked for the label changes on May 23-two days after the New England Journal of Medicine published a meta-analysis that found a 43% increase in risk of myocardial infarction among patients taking rosiglitazone.

The lead author of that analysis -- Steven E. Nissen, M.D., chairman of cardiovascular medicine at the Cleveland Clinic -- was aggressively questioned by Republican members of the committee who accused Dr. Nissen of sensationalizing what they characterized as questionable findings.

The Republicans also grilled Dr. Nissen over his decision to share his concerns about the safety of rosiglitazone with Waxman in February.

Rep. Darrell E. Issa (R-Calif.) was prosecutorial as he repeatedly attempted to limit Dr. Nissen to "yes" or "no" answers. Issa said that if Dr. Nissen had safety concerns about the drug, he should have taken those concerns to the FDA, not to committee staff appointed by Democrats.

Several times Issa and other Republicans pressed Dr. Nissen about whether he had shared his findings with Democrats on the committee before the meta-analysis was published.

Dr. Nissen repeatedly stated that his interest in rosiglitazone was purely that of a physician-scientist, whose goal was to disseminate information to both physicians and patients.

Moncef Slaoui, Ph.D., chairman of research and development for GlaxoSmithKline, presented the company's case testifying that rosiglitazone had demonstrated superiority over two diabetes drugs -- metformin and sulfynurea -- and that the company has gone out of its way to confirm the safety of rosiglitazone.

Dr. Slaoui testified that the interim results from the RECORD trial, published online last Thursday by the New England Journal of Medicine, provided reassuring data about the drug's safety. The study did not find a significant increase in MIs, but found a significant increase in heart failure. But three accompanying editorials pointed out that although the data did not confirm the risk found in the earlier meta-analysis, neither did they refute that finding.

Source: Diabetes In Control: American Society of Clinical Oncology Independent Satellite Symposium